Cytisinicline is under clinical development by Achieve Life Sciences and currently in Phase III for Smoking Cessation. According to GlobalData, Phase III drugs for Smoking Cessation does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Cytisinicline LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cytisinicline (Tabex) is under development for the treatment of smoking cessation. It is administered through oral route as a film coated tablet. The drug candidate acts by targeting alpha-4 and beta-2 nicotinic receptors.
It is under development for the treatment of nicotine E-cigarette cessation
Achieve Life Sciences overview
Achieve Life Sciences (ALS), is a pharmaceutical company that carries out production of advancing cytisinicline which helps people in battling nicotine addiction. In order to lessen the withdrawal symptoms and satisfaction brought on by smoking, cytisinicline binds to the same receptors as nicotine. The company also addresses global smoking health epidemic through the development and commercialization of cytisinicline for smoking cessation. It focuses on expanding to e-cigarettes or vaping. The company has an exclusive license and supply agreement with Sopharma for the development and marketing of cytisinicline. ALS is headquartered in Bothell, Washington, the US.
For a complete picture of Cytisinicline’s drug-specific PTSR and LoA scores, buy the report here.